On October 17, 2025, AbbVie announced the completion of its acquisition of Gilgamesh Pharmaceuticals' Bretisilocin, a move seen as strengthening its neurotherapeutics pipeline and supporting long-term growth ambitions[6][1]. Earlier in October, the FDA approved an expanded indication for RINVOQ®, enabling broader use in ulcerative colitis and Crohn's disease, which is expected to boost immunology revenues and offset competitive pressures[2]. These major company-specific developments contributed to AbbVie's stock closing at $229.57 (+1.19%) on October 17, 2025, outperforming the broader market's moderate rebound driven by easing US-China trade tensions and recovery in regional bank stocks. Analyst sentiment remains positive, with Raymond James reiterating an 'Outperform' rating on October 17 and consensus forecasts aligning with the current price level[3][4].